KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiCalibrazione approssimativaProbabilità implicita attualeBefore Jan 1, 2028 77%In testa tra 5 esiti
Qualita del mercato
45 / 100
Bassa qualitàVolume 24h
47 €
Liquidità
3,9K €
Liquidità mediaBid / Ask
32.0% / 37.0%
Spread
5.0 pt
Spread moderatoDati di mercato
Aggiornato 21 minuti fa
14 mag 26, 2:001 ott 26, 3:59
Trend
Solo fondi simulati, nessun denaro realeNon è consulenza finanziaria
Esito scelto
Before Oct 1, 202637%
Trend del volume
$532 lug14g di dati28 lug
Mercati Correlati
Will the FDA approve MDMA for PTSD?
0 €Before Jan 1, 2027: 10%KALSHI
KALSHI
Hantavirus pandemic in 2026?
106,1K €Sì: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
5,8K €26-27M: 73%POLYMARKET
POLYMARKET
New pandemic in 2026?
5,2K €Sì: 9%POLYMARKET
POLYMARKET
Measles cases in 2026?
2,4K €Above 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
2K €Sì: 6%KALSHI
KALSHIAttivi in questi argomenti
Regole
If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: